Python Metabolism: New Weight Loss & Anti-Aging Molecule Discovered

The remarkable metabolism of the python may unlock fresh pathways for healthy weight management and even combat age-related muscle loss. Recent research has identified a molecule in python blood that signals to the brain when we’ve had enough to eat, offering a potentially novel approach to appetite control.

A New Understanding of Satiety

In less than a decade, new weight loss medications have disrupted the market, assisting millions but often accompanied by side effects like nausea or digestive discomfort. But what if a similar level of appetite control could be achieved without these drawbacks? Scientists in the United States have identified a previously unknown molecule in python blood that signals to the brain that we are full.

These constrictor snakes, capable of reaching up to seven meters in length, can consume very large meals – an entire antelope, for example – in a single sitting and then go months, or even years, without feeding. The study isn’t aimed at replicating the dietary habits of these reptiles, but rather at the fact that pythons can alternate between fasting and feasting without lasting damage to their heart or muscles, which piqued the researchers’ interest.

pTOS: A Potential Alternative to GLP-1?

The molecule, called para-tyramine-O-sulfate (pTOS), was identified by Professor Leslie Leinwand and her team at the University of Colorado Boulder, even as studying the digestive system of these non-venomous snakes native to Africa, Asia, and Australia. Their findings, in collaboration with researchers from Stanford Medicine and Baylor University, were published in the journal Nature Metabolism.

Researchers observed that immediately after a meal, a python’s heart increases in volume by approximately 25%, and its metabolism surges, multiplying by 4,000 to aid digestion – all accompanied by a dramatic increase in pTOS levels in the blood (increasing more than 1,000-fold). In humans, pTOS as well increases after meals, but to a much more modest extent, by about two to five times.

This pTOS surge is part of the digestive process: the body utilizes an amino acid called tyrosine, which gut bacteria transform into a compound named tyramine. The liver then converts tyramine into pTOS, which travels to the brain and triggers the sensation of fullness, reducing appetite.

This molecule had previously gone unnoticed in laboratories because common research animals, like mice and rats, don’t naturally produce it after a meal.

GLP-1, the hormone targeted by medications like Ozempic and Wegovy, also helps the body experience full by slowing digestion and regulating blood sugar. Common side effects include nausea, digestive issues, and sometimes vomiting.

Weight Loss Without Metabolic Harm in Mice

In animal studies, mice administered pTOS ate less, and long-term treatment led to a decrease in body weight and food intake. These effects appeared without major changes in activity, energy expenditure, or blood sugar levels, suggesting that pTOS could be a promising avenue for obesity research. This research builds on earlier findings from November 2024, highlighted by Radio-Canada, which noted concerns about muscle loss associated with medications like Ozempic and Mounjaro (ICI Radio-Canada). The potential for pTOS to mitigate these effects is an area of ongoing investigation.

This discovery sheds light on a new biological mechanism that helps the body feel satiated after a meal. It could lead to future treatments that naturally reduce hunger and facilitate weight control. It also underscores the crucial role of gut bacteria in regulating metabolism and sending signals to the brain. As of now, pTOS has only been tested in mice, and its effects in humans have not yet been evaluated. The appetite-suppressing effect could also be diminished, or even absent, in individuals with prediabetes or type 2 diabetes, suggesting that the body’s natural satiety signal may not function as effectively in these conditions. A similar concern was raised in November 2024 by researchers at the University of Alberta, who noted a significant loss of muscle mass – up to 8.2% – in users of semaglutide (Frequence Medicale).

Implications for Muscle Health and Weight Management

The potential benefits of pTOS extend beyond weight loss. The ability of pythons to maintain muscle mass during periods of fasting and refeeding is particularly intriguing. Current weight loss medications, like Ozempic, have been linked to muscle loss, including cardiac muscle, raising health concerns (Doctissimo). If pTOS can mimic the python’s ability to preserve muscle while promoting weight loss, it could offer a significant advantage over existing treatments.

However, it’s important to note that the research is still in its early stages. The differences in physiology between snakes and humans are substantial. Further studies are needed to determine whether pTOS has the same effects in humans and whether it can be safely and effectively used as a therapeutic agent.

What’s Next?

The research team is currently focused on understanding the precise mechanisms by which pTOS signals the brain and how it interacts with other hormones and neurotransmitters involved in appetite regulation. Future studies will investigate the potential for developing pTOS-based therapies for obesity and related metabolic disorders. Clinical trials in humans are necessary to assess the safety and efficacy of pTOS and to determine the optimal dosage and delivery method. Researchers will also explore whether pTOS can be used to prevent or reverse muscle loss associated with aging or chronic disease.